- Home
- LFT vs GNLX Comparison
LFT vs GNLX Comparison
Compare LFT & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFT
- GNLX
- Stock Information
- Founded
- LFT 2012
- GNLX 2001
- Country
- LFT United States
- GNLX United States
- Employees
- LFT N/A
- GNLX N/A
- Industry
- LFT Real Estate Investment Trusts
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- LFT Real Estate
- GNLX Health Care
- Exchange
- LFT Nasdaq
- GNLX Nasdaq
- Market Cap
- LFT 109.9M
- GNLX 129.9M
- IPO Year
- LFT N/A
- GNLX 2023
- Fundamental
- Price
- LFT $2.29
- GNLX $3.34
- Analyst Decision
- LFT Hold
- GNLX Strong Buy
- Analyst Count
- LFT 2
- GNLX 5
- Target Price
- LFT N/A
- GNLX $16.20
- AVG Volume (30 Days)
- LFT 457.9K
- GNLX 151.6K
- Earning Date
- LFT 08-11-2025
- GNLX 08-13-2025
- Dividend Yield
- LFT 13.97%
- GNLX N/A
- EPS Growth
- LFT N/A
- GNLX N/A
- EPS
- LFT 0.20
- GNLX N/A
- Revenue
- LFT $27,066,283.00
- GNLX N/A
- Revenue This Year
- LFT $152.58
- GNLX N/A
- Revenue Next Year
- LFT N/A
- GNLX N/A
- P/E Ratio
- LFT $11.51
- GNLX N/A
- Revenue Growth
- LFT N/A
- GNLX N/A
- 52 Week Low
- LFT $2.05
- GNLX $1.60
- 52 Week High
- LFT $2.84
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- LFT 51.57
- GNLX 54.17
- Support Level
- LFT $2.06
- GNLX $3.23
- Resistance Level
- LFT $2.44
- GNLX $3.70
- Average True Range (ATR)
- LFT 0.07
- GNLX 0.28
- MACD
- LFT 0.04
- GNLX 0.00
- Stochastic Oscillator
- LFT 60.53
- GNLX 54.31
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.